Literature DB >> 12611781

Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review.

A Wieck1, P M Haddad.   

Abstract

BACKGROUND: Hyperprolactinaemia has for decades been an inevitable and neglected side-effect of antipsychotic medication. The recent introduction of prolactin-sparing antipsychotic agents makes a re-examination of this problem timely. AIMS: To review the literature on antipsychotic-induced hyperprolactinaemia and its consequences.
METHOD: A search was made of the Medline database (1966-2002) for key articles, supplemented by cross-referencing.
RESULTS: During antipsychotic treatment prolactin concentrations can rise to ten times normal levels or above, and existing data indicate that 17-78% of female patients have amenorrhoea with or without galactorrhoea. Survey data, however, suggest that clinicians underestimate the prevalence of these conditions. Long-term consequences of antipsychotic-related hypo-oestrogenism require further research but are likely to include premature bone loss.
CONCLUSIONS: Antipsychotic-induced hyperprolactinaemia should become a focus of interest in the drug treatment of psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12611781     DOI: 10.1192/bjp.182.3.199

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  27 in total

1.  Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics.

Authors:  Donna R Halloran; Jason Swindle; Steve K Takemoto; Mark A Schnitzler
Journal:  Clin Pediatr (Phila)       Date:  2010-01-28       Impact factor: 1.168

2.  The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects.

Authors:  Stefan Cohrs; Cornelia Röher; Wolfgang Jordan; Andreas Meier; Gerald Huether; Wolfgang Wuttke; Eckart Rüther; Andrea Rodenbeck
Journal:  Psychopharmacology (Berl)       Date:  2006-01-24       Impact factor: 4.530

3.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

4.  Antidepressant use and circulating prolactin levels.

Authors:  Katherine W Reeves; Olivia I Okereke; Jing Qian; Shelley S Tworoger; Megan S Rice; Susan E Hankinson
Journal:  Cancer Causes Control       Date:  2016-05-10       Impact factor: 2.506

5.  Quetiapine-induced galactorrhea with normal prolactin level in an adult female patient.

Authors:  Saira Mushtaq; Sadaf Khan; Harshad Patel
Journal:  Prim Care Companion CNS Disord       Date:  2012-04-19

Review 6.  Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles?

Authors:  Wolfgang Aichhorn; Alexandra B Whitworth; Elisabeth M Weiss; Josef Marksteiner
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 7.  Pharmacological Management of Bipolar Disorder in Pregnancy.

Authors:  Sarah C Jones; Ian Jones
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 8.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

9.  Depression, Antidepressant Use, and Postmenopausal Breast Cancer Risk.

Authors:  Susan B Brown; Susan E Hankinson; Kathleen F Arcaro; Jing Qian; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

Review 10.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.